In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of NeuroSense Therapeutics Ltd (NASDAQ: NRSN) closed at $1.12 in the last session, down -5.84% from day before closing price of $1.19. In other words, the price has decreased by -$5.84 from its previous closing price. On the day, 96203.0 shares were traded. NRSN stock price reached its highest trading level at $1.165 during the session, while it also had its lowest trading level at $1.1.
Ratios:
We take a closer look at NRSN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.21 and its Current Ratio is at 0.21.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRSN now has a Market Capitalization of 25967588 and an Enterprise Value of 19410706.
Stock Price History:
The Beta on a monthly basis for NRSN is 1.29, which has changed by 0.20474136 over the last 52 weeks, in comparison to a change of 0.23806548 over the same period for the S&P500. Over the past 52 weeks, NRSN has reached a high of $2.33, while it has fallen to a 52-week low of $0.51. The 50-Day Moving Average of the stock is -2.66%, while the 200-Day Moving Average is calculated to be -1.77%.
Shares Statistics:
According to the various share statistics, NRSN traded on average about 292.47K shares per day over the past 3-months and 211970 shares per day over the past 10 days. A total of 19.81M shares are outstanding, with a floating share count of 13.48M. Insiders hold about 34.90% of the company’s shares, while institutions hold 1.09% stake in the company. Shares short for NRSN as of 1732838400 were 324354 with a Short Ratio of 0.99, compared to 1730332800 on 382959. Therefore, it implies a Short% of Shares Outstanding of 324354 and a Short% of Float of 1.8399999999999999.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
